In vitro experiments confirmed that FKBP10 promotes tumor cell proliferation and clonogenicity.<h4>Conclusions</h4>FKBP10 is closely linked to tumor progression and treatment response by contributing to metabolic reprogramming, immunosuppressive microenvironment modulation, and programmed cell death regulation, supporting its potential as a biomarker and therapeutic target for predicting prognosis, treatment response, and immunotherapy outcomes. Here, FKBP10 is linked to neoplasm.